Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020752

« Back to Dashboard

NDA 020752 describes PEPCID RPD, which is a drug marketed by Merck and is included in one NDA. Additional details are available on the PEPCID RPD profile page.

The generic ingredient in PEPCID RPD is famotidine. There are eighteen drug master file entries for this compound. One hundred and seventeen suppliers are listed for this compound. Additional details are available on the famotidine profile page.

Summary for 020752

Tradename:	PEPCID RPD
Applicant:	Merck
Ingredient:	famotidine
Patents:	0
Therapeutic Class:	Gastrointestinal Agents
Formulation / Manufacturing:	see details

Medical Subject Heading (MeSH) Categories for 020752

Anti-Ulcer Agents
Histamine H2 Antagonists

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	20MG
Approval Date:	May 28, 1998	TE:		RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	40MG
Approval Date:	May 28, 1998	TE:		RLD:	No

Expired US Patents for NDA 020752

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.